Clinical Trial

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Protocol Amendment History 1 change
notable Trial sites reduced: 82 -> 40 locations 2026-06-11
Trial Details
NCT Number NCT07015242
Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Conditions Lymphoma
Enrollment 65 participants
Start Date 2025-11-06
Primary Completion 2028-01-09 (estimated)
Study Completion 2028-12-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-29